This is a working overview of research chemical, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-09 and is reviewed periodically as new material appears.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
The MIM mode, on the other hand will usually employ a much longer dwell time on each ion, and as a result, accurate quantification is possible to the parts per billion (ppb) level. SIFT-MS utilises an extremely soft ionisation process which greatly simplifies the resulting spectra and thereby facilitates the analysis of complex mixtures of gases, such as human breath. Another very soft ionization technique is secondary electrospray ionization (SESI-MS). For example, even proton-transfer-reaction mass spectrometry (PTR-MS), another soft ionisation technology that uses the H3O+ reagent ion, has been shown to give considerably more product ion fragmentation than SIFT-MS. Another key feature of SIFT-MS is the upstream mass quadrupole, which allows the use of multiple precursor ions. The ability to use three precursor ions, H3O+, NO+ and O2+, to obtain three different spectra is extremely valuable because it allows the operator to analyse a much wider variety of compounds. An example of this is methane, which cannot be analysed using H3O+ as a precursor ion (because it has a proton affinity of 543.5kJ/mol, somewhat less than that of H2O), but can be analysed using O2+. Furthermore, the parallel use of three precursor ions may allow the operator to distinguish between two or more compounds that react to produce ions of the same mass-to-charge ratio in certain spectra. For example, dimethyl sulfide (C2H6S, 62 amu) accepts a proton when it reacts with H3O+ to generate C2H7S+ product ions which appear at m/z 63 in the resulting spectrum.
Thebacon is an opioid agonist narcotic analgesic of the middle range and a strong antitussive, primarily used in Europe, although it is no longer in common use. Currently, dihydrocodeine and nicocodeine are used as second-line codeine replacements. The other dihydromorphinone used as an antitussive is hydromorphone (Dilaudid cough syrup); the other narcotic antitussives are either more directly related to codeine or not related at all (open chain methadone relatives and thiambutenes). Thebacon is indicated for moderate to moderately severe pain and dry painful coughing, like hydrocodone. It has a duration of action in the range of 5 to 9 hours and doses typically start at 5 mg q6h. For both pain and coughing, thebacon can be made more effective along with NSAIDs, muscle relaxants, and/or antihistamines like tripelennamine, hydroxyzine, promethazine, phenyltoloxamine and chlorpheniramine.
== Side effects == General side effects that have been reported with enobosarm in clinical trials include headache, fatigue, anemia, nausea, diarrhea, and back pain. Enobosarm has shown dose-related adverse effects on serum lipids, sex hormone and gonadotropin levels, and carrier protein levels in clinical trials. It decreases HDL cholesterol levels, reducing them dose-dependently by 17% at a dose of 1 mg/day and by 27% at a dose of 3 mg/day. Decreases in total cholesterol levels and in triglyceride levels have also been seen, whereas LDL cholesterol levels are unchanged. In healthy elderly men, total testosterone levels decreased significantly at doses of 1 and 3 mg/day (-31% and -57%, respectively), whereas levels of free testosterone, dihydrotestosterone (DHT), estradiol, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) did not change significantly at doses up to 3 mg/day. In healthy postmenopausal women, LH and FSH decreased significantly only at the 3 mg/day dose (-17% and -30%, respectively), whereas levels of total testosterone, free testosterone, DHT, and estradiol did not clearly change relative to placebo. SHBG levels were lowered at doses of 1 to 3 mg/day, decreasing dramatically by 61% in men and by 80% in women at the 3 mg/day dose. For comparison, testosterone enanthate by intramuscular injection at a highly supraphysiological dose of 600 mg/week resulted in only a 31% decrease in SHBG levels. Despite the large changes in SHBG levels, levels of free testosterone did not significantly change in either men or women.
== Further development == Partition chromatography allowed further developments of column chromatography, and inspired new forms of chromatography such as countercurrent distribution, paper chromatography, and gas chromatography. Commercial counter-current distribution instruments were used for many important discoveries The introduction of paper chromatography was an important analytical technique which gave rise to thin-layer chromatography. Finally, gas-liquid chromatography, a fundamental technique in modern analytical chemistry, was described by Martin with coauthors A. T. James and G. Howard Smith in 1952. The stationary phase can be changed to change the separation characteristics. By chemically bonding alkane functional groups to silica gel, we obtain reversed-phase chromatography. In 1944, Lyman C. Craig accomplished the original goal of Martin and Synge: column chromatography with two free-flowing liquid phases.
== Work == In 1934 Flory joined the Central Department of Dupont and Company working with Wallace H. Carothers. After Carothers' death in 1937, Flory worked for two years at the Basic Research Laboratory located in the University of Cincinnati. During World War II, there was a need for research to develop synthetic rubber, so Flory joined the Esso Laboratories of the Standard Oil Development Company. From 1943 to 1948 Flory worked in the polymer research team of the Goodyear Tire and Rubber Company. In 1948, Flory gave the George Fisher Baker lectures at Cornell University, and subsequently joined the university as a professor. In 1957, Flory and his family moved to Pittsburgh, Pennsylvania, where Flory was executive director of research at the Mellon Institute of Industrial Research. In 1961, he took up a professorship at Stanford University in the department of chemistry. After retirement, Flory remained active in the world of chemistry, running research labs both in Stanford, and IBM.
Sources: en.wikipedia.org
Food and Drug Administration (FDA) does not approve bromide for the treatment of any disease, and sodium bromide was removed from over-the-counter (OTC) sedative products like Bromo-Seltzer, in 1975. FDA banned organic bromides from OTC sleep aids in 1989. Commercially available organobromine pharmaceuticals include the vasodilator nicergoline, the sedative brotizolam, the anticancer agent pipobroman, and the antiseptic merbromin. Otherwise, organobromine compounds are rarely pharmaceutically useful, in contrast to the situation for organofluorine compounds. Several drugs are produced as the bromide (or equivalents, hydrobromide) salts, but in such cases bromide serves as an innocuous counterion of no biological significance. Organobromine compounds are used as psychedelic and designer drugs such as 2C-B, Bromo-DragonFLY, and 4-Bromomethcathinone. Other uses of organobromine compounds include high-density drilling fluids, dyes (such as Tyrian purple and the indicator bromothymol blue), and pharmaceuticals. Bromine itself, as well as some of its compounds, are used in water treatment, and is the precursor of a variety of inorganic compounds with an enormous number of applications (e.g. silver bromide for photography). Zinc–bromine batteries are hybrid flow batteries used for stationary electrical power backup and storage; from household scale to industrial scale. Bromine is used in cooling towers (in place of chlorine) for controlling bacteria, algae, fungi, and zebra mussels.
The first company to use such method is Evonik company in 2000. The enzyme Lipase-CalB in its immobilized state is actually used in other pharmaceutical applications for the production of Odanacatib, and Sofosbuvir.
Glycoproteins and Glycolipids found on the cell surface play a critical role in bacterial and viral recognition. They are involved in cellular signaling pathways and modulate cell function. They are important in innate immunity. They determine cancer development. They orchestrate the cellular fate, inhibit proliferation, regulate circulation and invasion. They affect the stability and folding of proteins. They affect the pathway and fate of glycoproteins. There are many glycan-specific diseases, often hereditary diseases. There are important medical applications of aspects of glycomics:
Delta atracotoxin (δ-ACTX-Ar1, robustoxin, or robustotoxin) is a low-molecular mass neurotoxic polypeptide found in the venom of the Sydney funnel-web spider (Atrax robustus). Delta atracotoxin produces potentially fatal neurotoxic symptoms in primates, by slowing the inactivation of sodium ion channels in autonomic and motor neurons. In the spiders' intended insect prey, the toxin exerts this same activity upon calcium ion channels. The structure of atracotoxin comprises a core beta region with a cystine knot motif, a feature seen in other neurotoxic polypeptides.
{\displaystyle {\begin{aligned}x:\ &\rho \left({\partial _{t}u_{x}}+u_{x}\,{\partial _{x}u_{x}}+u_{y}\,{\partial _{y}u_{x}}+u_{z}\,{\partial _{z}u_{x}}\right)\\&\quad =-\partial _{x}p+\mu \left({\partial _{x}^{2}u_{x}}+{\partial _{y}^{2}u_{x}}+{\partial _{z}^{2}u_{x}}\right)+{\frac {1}{3}}\mu \ \partial _{x}\left({\partial _{x}u_{x}}+{\partial _{y}u_{y}}+{\partial _{z}u_{z}}\right)+\rho g_{x}\\\end{aligned}}}
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.